CND Life Sciences completes its Series Seed 3 round, raising a total of $12.5 million in equity


CND Life Sciences, a medical technology company that has pioneered the development of reliable skin-based tests to assist clinicians in diagnosing neurodegenerative disorders such as Parkinson’s disease and dementia with Lewy bodies, announced today the completion of a $4.5 million Series Seed 3 equity financing round.

This additional funding brings the Company’s total Seed funding to $12.5 million, which will be used to accelerate the commercialization of the Syn-One Test®, the first commercially available test that can detect abnormal alpha-synuclein aggregation through a simple skin biopsy.

Several existing and new investors participated in the round, and Top Corner Capital provided a concurrent financing vehicle, demonstrating their enthusiasm for CND’s rapid growth and promising future.

CND creates and sells skin-based tests to assist clinicians across the country in accurately diagnosing and treating neurologic disorders such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and peripheral neuropathies.

According to peer-reviewed studies, many of these disorders have a high rate of misdiagnosis, especially early in the disease process, resulting in suboptimal treatment for patients and significant frustration for family caregivers. The Syn-One Test is powered by technology licensed from Boston’s Beth Israel Deaconess Medical Center.

CND Life Sciences is committed to assisting in the care of patients who have been diagnosed with a neurodegenerative disease or other neurological condition. CND, based in Scottsdale, Arizona, launched the Syn-One Test in 2019 as the world’s first commercially available test to detect, visualize, and quantify phosphorylated alpha-synuclein in cutaneous nerves.

The test, which analyzes small skin biopsies taken from the patient in a doctor’s office, helps to diagnose synucleinopathies such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder.

The Syn-One Test leverages a decade of published science from leading academic institutions in multiple countries, with data demonstrating high sensitivity and specificity.

Related Stories